Triggered Nanoparticles for Deep Tissue Chemotherapy Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering chemotherapy to normal tissue surrounding a cancerous tumor after surgical removal are ineffective, as they rely on diffusion, which only penetrates 1-2 mm deep, inadequate for addressing precancerous or cancerous cells remaining in the tissue margin.
Innovation Solution
The use of triggered nanoparticles for intravascular triggered release, combined with a trigger energy delivery device that exposes the surgical cavity and surrounding tissue up to 0.5-3 cm deep to trigger energy, allowing for rapid drug release within seconds to effectively target and kill remaining cancerous and precancerous cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If diffusion-based chemotherapy delivery is used, then the method is simple, but the penetration depth is limited to 1-2 mm
Solution Approach 1:
The patent introduces an intermediary substance (chemotherapy agent) that is delivered through the bloodstream to the surgical cavity. The drug is administered systemically and accumulates in the target tissue through blood flow, enabling deep penetration without direct local application. This mediator approach allows the chemotherapy to reach depths of 0.5-3 cm by traveling through the vascular system rather than diffusing from the surface.
Solution Approach 2:
The patent utilizes the hydraulic system of the bloodstream to deliver chemotherapy deep into tissue. By administering the drug intravenously, it rides the blood flow (hydraulic transport) to reach the surgical cavity and surrounding tissue at depths up to 3 cm, bypassing the limitation of surface-based diffusion methods.
2Ease of operation
If direct chemotherapy application to surgical cavity is used, then the treatment is localized, but the penetration depth remains insufficient at 1-2 mm
Solution Approach 1:
The patent makes the chemotherapy administration system multi-functional by combining systemic delivery with localized targeting. The same intravenous administration route that delivers drug throughout the body also specifically targets the surgical cavity through blood flow accumulation, achieving both systemic coverage and localized deep penetration in one approach.
Solution Approach 2:
The patent transitions from surface-level (2D) diffusion to three-dimensional (3D) vascular transport. Instead of spreading chemotherapy across the tissue surface where it penetrates only 1-2 mm, the drug is delivered through the 3D vascular network, allowing it to reach deep into tissue volumes at depths of 0.5-3 cm through blood flow pathways.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the delivery of a large chemotherapy dose to the surgical cavity and surrounding tissue, effectively reducing the risk of local tumor recurrence by targeting and eliminating precancerous and cancerous cells at depths beyond the limitations of traditional diffusion-based methods.
Implementation Method 1
triggered drug delivery particles are administered into the systemic blood circulation... the surgical cavity is exposed to the trigger signal to induce localized release of the chemotherapy agent
Implementation Method 2
hyperthermia in the range ideal for chemotherapy release from those heat-triggered nanoparticles (typically 40-45°C) will be applied to the surgical cavity and deeper surrounding tissue
Implementation Method 3
heat-triggered nanoparticles such as thermosensitive liposomes... majority of drug released within 10 s of exposure to trigger energy
Data Source
AI summary
A method and apparatus for the targeted delivery of chemotherapy to a surgical cavity, consisting of a triggered nanoparticle encapsulating a therapeutic agent and an energy delivery device that applied trigger energy to the surgical cavity. Following surgical removal of a cancerous tumor, the nanoparticle is administered, and the energy delivery device applies trigger energy to the surgical cavity and proximal tissue. The goal is the delivery of a therapeutic drug dose to cancerous and precancerous cells remaining after surgery, to prevent local tumor recurrence.